Wednesday, October 14, 2026

October 2026 Random Ramblings

October 2026 market commentary covers SOLS’s cancelled merger, a hypothetical Starbucks-Chipotle deal, Russell 2000 weakness and AI premiums for Oura and home builders.

SOLS $9.7BCMG $39B

Yet Another Value Podcast Oct 14 87 clicks

Oct 14 SHEN $556M

Private Equity Prints Multibaggers With This Pattern. No One is Talking About It.

Phynvesting 20 clicks

Oct 14 COHR $52B

Coherent | Management Call

P Equity Research 19 clicks

From X

@LaughingH20Cap Oct 14 5 clicks

Laughing Water Capital on X

@bufetmastermind @secretlyaninja @mbamcnulty maybe i don't. I'd appreciate if you could explain. they had said 50% FCF margin on $1B in sales. $LQDA is still going to get to $1B in sales. Its just going to take longer. Tell me why 50% FCF margins are not in play. Bonus points if you can tell why they won't reduce costs

@HaydenCapital Oct 14 1 click

Fred Liu on X

Is Tiktok Shop slowing? J&T Express just reported SE Asia parcel volumes, and are flat for the year at ~31M per day for the last few qtrs. They're guiding to 50-55% full year growth, implying Q4 holiday season only ramps to 33-37M parcels. Evidence Shopee's VIP & logistics investments are working? $SE $1519.HK

@hkuppy Oct 14 1 click

Kuppy on X

I’m sure that $CRWV is money good on funding its gazillions of chip purchase orders, as long as someone funds $CRWV…🤭🤭 https://t.co/TOnS6iGurC

@StableBread Oct 14

Fajasy on X

Archimedes Tech SPAC Partners II $ATII, the SPAC taking atomic-scale coatings maker Forge Nano public, amended the $100M lead commitment in its PIPE on October 13, three days before the October 16 merger vote. Alyeska, the Chicago hedge fund behind that $100M, will now take 7,031,175 of its 10M shares as pre-funded warrants, up from the 3M planned as of September 24. Those warrants cost $0.0001/share to exercise and never expire, but they don't vote until exercised, and Alyeska can cap its ownership at 4.9%, 9.9%, or 19.9% of the shares. ATII and its sponsor, with the consent of BTIG (the bank that ran ATII's IPO), also waived the transfer restrictions on the 3M founder shares the sponsor hands Alyeska for free at close. Counting the founder share transfer, Alyeska's effective cost is $7.69/share, and the S-4 (the merger filing) says so directly. So the $100M still lands at close, but the fund providing it got more flexible terms the day before ATII holders had to decide whether to redeem.

@gnoble79 Oct 14 8 clicks

George Noble on X

Keith, you are a total POS. You belong in jail for securities fraud. I own you. You laughed at me first shorting $OOEN at 8. You are such a pathetic, odious pile of garbage. So pathetic. The entire world is laughing at you. Thanks for playing. $OPEN @rabois @ericjackson @APompliano @

@BrokenMoats Oct 14 4 clicks

Broken Moats on X

Hottest trade in the past month.....retail stocks Seems odd with rates and oil and diesel moves over the same time frame. And these are not bounces from being oversold these are double digit moves in most cases to new highs while dpz struggled on their print this week, stocks like DKS collapsed around the time this trade started. Bifurcation in retail in recent weeks that seems to be favoring low quality. Something to watch for a reversal soon $KSS $FIGS $URBN $SHOP

@calvinblissett Oct 14 2 clicks

Calvin Blissett on X

@valuedontlie Forgive me I haven’t done the work I may soon, isn’t the whole point of $VITL is having a brand and being specialized to insulate it from cyclicality to see degree? I’m one of those people who pay up for pasture raised no matter what

@BlueDuckCap Oct 14 5 clicks

BDC on X

It's been 189 days since @evanspiegel had a confirmed sale. The longest sales void ever, per what we can discern from filings. He's in a blackout window now. If the sales do not resume post Q3 window opening then that would seem bullish. We would love an insider buy, too. Evan buys stock here we would think $SNAP is +10% on that day. At least. Not advice. Just pointing out the cadence of form 4's and lack of historical insider buying.

Morgan Stanley Direct Lending: Discount Is Attractive, But Credit Has Not Stabilized; Hold

Morgan Stanley Direct Lending trades at a 32% NAV discount as non-accruals reach 2.9%, NII and NAV decline, and dividend coverage falls to…

MSDL $1.5B

Rubicon Associates Oct 14 1 click

Research Roundup Vol. LVI

Howmet Aerospace is framed as a beneficiary of turbine and aircraft-engine demand, while J.B.

HWM $88BJBHT $22B

Monte Independent Investment Research Oct 14 14 clicks

Lennar: The Misstep Is Temporary, the Operating Machine Is Not

Lennar cut build times to 116 days and adopted an asset-light land model, while gross margin fell to 15.8% from 27.5% as land costs rose.

LEN $17B

Latticework by MOI Global Oct 14 16 clicks

Lennar, Part One: The Story

Lennar grew from a Miami builder into one of America’s two largest homebuilders, controlling land largely through options and land banks…

LEN $17B

Latticework by MOI Global Oct 14 15 clicks

Lennar, Part Two: The Deep Dive

Lennar’s second audio program examines the homebuilder’s business for professional investors and housing analysts.

LEN $17B

Latticework by MOI Global Oct 14 13 clicks

Insider activity September 2026

Asian insider buying rose 19% to US$2.4 billion across 930 September transactions, led by Grab CEO Anthony Tan’s US$30 million purchase…

GRAB $12B

Asian Century Stocks Oct 14 7 clicks

Rollins (ROL), Verisure (VSURE), and the cost of standing still (Part 2, Verisure)

Verisure’s 6.38 million monitored-alarm subscribers generate 90% recurring revenue, while its disclosed acquisition costs and 6%-8% churn…

ROL $15B

Best Anchor Stocks Oct 13 24 clicks

SED Energy: The 40% Dividend. Signal or Noise?

SED Energy's proposed Ventura merger projects a 22% to 40% dividend yield, but idle tender barges, debt and repayments materially reduce…

SBDXF $498M

Cannibal Stocks Oct 13 8 clicks

BridgeBio: Maintaining 'Strong Buy' Additional Encaleret Data ADH1 And Three Expected FDA Reviews

BridgeBio Pharma reported Q2 revenue of $243.7 million and has three Priority Review NDAs, while $1 billion in convertible preferred…

BBIO $13B

Terry Chrisomalis Oct 13 2 clicks

Monte Investments Market Brief Vol. CXXXI

Park Aerospace reported 27% revenue growth and 72% EPS growth, supported by composite materials for Airbus engines and PAC-3 rocket motors.

PKE $571M

Monte Independent Investment Research Oct 13 5 clicks

SLS · short

Sellas Life Sciences Group I

SELLAS Life Sciences Group faces a short case arguing that even a strong clinical outcome does not support its current valuation.

SLS $2.3B

Value Investors Club May 25

A 4x in 4 Years Surfing the Data Center Tsunami? ($TSSI)

Total Site Solutions ($TSSI) depends on Dell for 96% of revenue; the 4x thesis rests on Dell expanding modular data centers amid AI-driven…

TSSI $200M

Multibagger Monitor Apr 16 4 clicks

Summary of Q4 Restaurant Conference Calls

Restaurant operators reported improving traffic, accelerating unit growth and higher advertising spend, while wage inflation ran 4-5% and…

EAT $8.6B

Investing 501 Mar 14

A Mexican Blue Chip Bargain

Grupo Herdez, a MXN 15.2 billion Mexican food company, pairs dominant grocery brands with McCormick, Barilla and Hormel joint ventures.

GUZOF $954M

Exploring with Alluvial Capital Mar 7

One Hour Analysis: Driven Brands Holdings ($DRVN), Road Kill or Road to Redemption?

Driven Brands’ 5,000-location auto-service network pairs strong Maintenance results with Car Wash and collision-unit fixes after DRVN fell…

DRVN $1.9B

Investing 501 Feb 25

Quality Investing Outside the Blue Chips

Rand Worldwide, an Autodesk reseller, grew revenue from $116 million to $306 million while using less equity; expired three-year…

RWWI $251M

Exploring with Alluvial Capital Dec 26 1 click

Highlights from Darden Restaurants' Q2 '23 Conference Call

Darden Restaurants posted 2.8% same-store sales growth as Olive Garden and LongHorn outperformed a softer casual-dining market, while…

DRI $24B

Investing 501 Dec 17

Sarepta Risk and the FDA

Sarepta’s Exondys 51 approval despite a 12-patient trial frames FDA regulatory risk and a call to remove Commissioner Robert Califf.

SRPT $1.8B

John Hempton's Newsletter Oct 31 1 click

A Value Trap, an Ancient Stock Pitch, a Glimpse Into The Past

Four Corners’ insider-backed asset sale cut shareholder proceeds to roughly 80% of its prior share price. A 2016 Wilh.

FCPT $2.7B

Exploring with Alluvial Capital Sep 27

Does anyone remember when Alnylam went up 50 percent in a day on a phase three result

Alnylam’s 2022 50% phase-three gain faces FDA advisory-panel scrutiny over its amyloidosis drug’s label extension.

ALNY $31B

John Hempton's Newsletter Sep 12

Wednesday, October 14, 2026

Laughing Water Capital on X

Fred Liu on X

Kuppy on X

Fajasy on X

George Noble on X

Broken Moats on X

Calvin Blissett on X

BDC on X

Investor Letters

Publications we follow

Newsletters 108

YouTube 4

Blogs 17

Seeking Alpha 52 of 238

X accounts we follow

Investor letters we follow

Sectors